ETF Building Blocks Channel Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
Innovative ETFs Channel Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs By Max ChenNovember 5, 2021
Innovative ETFs Channel A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Beyond Basic Beta Channel Artificial Intelligence Set to Transform the Pharmaceutical Industry By Ben HernandezJune 1, 2021
Beyond Basic Beta Channel Pharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More Advances By Ben HernandezMarch 4, 2021
Innovative ETFs Channel Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
Beyond Basic Beta Channel Assessing Political Outcomes for Pharmaceuticals ETFs By Tom LydonJuly 21, 2020
Beyond Basic Beta Channel Expect Pharmaceuticals M&A Activity to Rebound After COVID-19 Eases By Tom LydonApril 17, 2020
Webcasts An Active ETF Approach to Target Innovations in Next Generation Sequencing By Max ChenNovember 14, 2019
Beyond Basic Beta Channel 8 ETFs to Capture Opportunities in Healthcare Sector By Max ChenAugust 22, 2019
Innovative ETFs Channel Biotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing Rule By Max ChenJuly 9, 2019
Innovative ETFs Channel AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs By Max ChenJune 25, 2019
Innovative ETFs Channel Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results By Max ChenFebruary 28, 2019
Core Equity Channel Healthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak Outlook By Max ChenJanuary 23, 2019
